-DOCSTART- -X- O
Sepsis -X- _ O
involves -X- _ O
a -X- _ O
disordered -X- _ O
host -X- _ O
response -X- _ O
to -X- _ O
systemic -X- _ O
infection -X- _ O
leading -X- _ O
to -X- _ O
high -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
Despite -X- _ O
intense -X- _ O
research -X- _ O
, -X- _ O
targeted -X- _ O
sepsis -X- _ B-Intervention
therapies -X- _ I-Intervention
beyond -X- _ O
antibiotics -X- _ O
have -X- _ O
remained -X- _ O
elusive. -X- _ O
The -X- _ O
cornerstone -X- _ O
of -X- _ O
sepsis -X- _ O
research -X- _ O
is -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
animal -X- _ O
models -X- _ O
to -X- _ O
mimic -X- _ O
human -X- _ O
bacterial -X- _ O
infections -X- _ O
and -X- _ O
test -X- _ O
novel -X- _ O
pharmacologic -X- _ O
targets. -X- _ O
Nonhuman -X- _ B-Patient
primates -X- _ I-Patient
( -X- _ I-Patient
NHPs -X- _ I-Patient
) -X- _ I-Patient
have -X- _ O
served -X- _ O
as -X- _ O
an -X- _ O
attractive -X- _ O
, -X- _ O
but -X- _ O
expensive -X- _ O
, -X- _ O
animal -X- _ O
to -X- _ O
model -X- _ O
human -X- _ O
bacterial -X- _ O
infections -X- _ O
due -X- _ O
to -X- _ O
their -X- _ O
nearly -X- _ O
identical -X- _ O
cardiopulmonary -X- _ O
anatomy -X- _ O
and -X- _ O
physiology -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
host -X- _ O
response -X- _ O
to -X- _ O
infection. -X- _ O
Several -X- _ O
NHP -X- _ O
species -X- _ O
have -X- _ O
provided -X- _ O
substantial -X- _ O
insight -X- _ O
into -X- _ O
sepsis-mediated -X- _ B-Outcome
inflammation -X- _ I-Outcome
, -X- _ I-Outcome
endothelial -X- _ I-Outcome
dysfunction -X- _ I-Outcome
, -X- _ I-Outcome
acute -X- _ I-Outcome
lung -X- _ I-Outcome
injury -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
multi-organ -X- _ I-Outcome
failure. -X- _ I-Outcome
The -X- _ O
use -X- _ O
of -X- _ O
NHPs -X- _ O
has -X- _ O
usually -X- _ O
focused -X- _ O
on -X- _ O
translating -X- _ O
therapies -X- _ O
from -X- _ O
early -X- _ O
preclinical -X- _ O
models -X- _ O
to -X- _ O
human -X- _ O
clinical -X- _ O
trials. -X- _ O
However -X- _ O
, -X- _ O
despite -X- _ O
successful -X- _ O
sepsis -X- _ O
interventions -X- _ O
in -X- _ O
NHP -X- _ O
models -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
still -X- _ O
no -X- _ O
FDA-approved -X- _ O
sepsis -X- _ B-Intervention
therapies. -X- _ I-Intervention
This -X- _ O
review -X- _ O
highlights -X- _ O
major -X- _ O
NHP -X- _ O
models -X- _ O
of -X- _ O
bacterial -X- _ O
sepsis -X- _ O
and -X- _ O
their -X- _ O
relevance -X- _ O
to -X- _ O
clinical -X- _ O
medicine -X- _ O
. -X- _ O

